Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat

详细信息    查看全文

• 作者：Keming Gao ; Chengmei Yuan ; Renrong Wu ; Jun Chen ; Zuowei Wang…
• 关键词：bipolar depression ; atypical antipsychotic ; number needed to treat ; efficacy ; tolerability ; weight gain ; somnolence ; extrapyramidal side ; effects ; akathisia
• 刊名：Neuroscience Bulletin
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：31
• 期：5
• 页码：572-588
• 全文大小：282 KB
• 参考文献：[1]Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002, 59: 530-37.CrossRef PubMed
  [2]Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003, 60: 261-69.CrossRef PubMed
  [3]Calabrese JR, Hirschfeld RM, Reed M, Davies MA, Frye MA, Keck PE, et al. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: Results of a U.S. community-based sample. J Clin Psychiatry 2004, 65: 1499-504.CrossRef PubMed
  [4]Gao K, Gajwani P, Elhaj O, Calabrese JR. Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry 2005, 66: 1376-385.CrossRef PubMed
  [5]Gao K, Wu R, Grunze H, Calabrese JR. Pharmacological Treatment of Acute Bipolar Depression. In: Yildiz A, Ruiz P, Nemeroff C (Eds.). Bipolar Book: History, Neurobiology, and Treatment. New York: Oxford University Press (in press).
  [6]Gao K, Kemp DE, Wu R, Calabrese JR. Mood stabilizers. In: Tasman AJ, Lieberman J, Kay J, First M, Riba M (Eds.). Psyschiatry. 4th Ed. Chichester, West Sussex, UK: Wiley-Blackwell (in press).
  [7]Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Kemp DE, Calabrese JR. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 2008, 69: 302-09.CrossRef PubMed
  [8]Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008, 28: 203-09.PubMed Central CrossRef PubMed
  [9]Wang Z, Kemp DE, Chan PK, Fang Y, Ganocy SJ, Calabrese JR, et al. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. Int J Neuropsychopharmacol 2011, 14: 131-42.PubMed Central CrossRef PubMed
  [10]Gao K, Kemp DE, Fein E, Wang Z, Fang Y, Ganocy SJ, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2011, 72: 1063-071.PubMed Central CrossRef PubMed
  [11]Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 2014, 155: 20-7.CrossRef PubMed
  [12]Carmody TJ, Rush AJ, Bernstein I, Warden D, Brannan S, Burnham D, et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006, 16: 601-11.PubMed Central CrossRef PubMed
  [13]McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997, 126: 712-20.CrossRef PubMed
  [14]Wu R, Kemp DE, Sajatovic M, Zhao J, Calabrese JR, Gao K. Communication of potential benefits and harm to patients and payers in psychiatry: a review and commentary. Clin Ther 2011, 33: B62-6.CrossRef PubMed
  [15]Cohen LS. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Erlbaum, 1988.
  [16]Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar depression. Arch Gen Psychiatry 2003, 60: 1079-088.CrossRef PubMed
  [17]Tohen M, McDonnell DP, Case M, Kanba S, Ha K, Fang YR, et al. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry 2012, 201: 376-82.CrossRef PubMed
  [18]Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, et al. Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study. BMC Psychiatry 2013, 13: 138.PubMed Central CrossRef PubMed
  [19]Brown EB, McElroy SL, Keck PE Jr, Deldar A, Adams DH, Tohen M, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006, 67: 1025-033.CrossRef PubMed
  [20]Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A andomized, double-blind, placebocontrolled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162: 1351-360.CrossRef PubMed
  [21]Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the
• 作者单位：Keming Gao (1)
  Chengmei Yuan (2)
  Renrong Wu (3)
  Jun Chen (2)
  Zuowei Wang (4)
  Yiru Fang (2)
  Joseph R. Calabrese (1)
  
  1. Department of Psychiatry, Case Western Reserve University School of Medicine and Mood Disorders Program, University Hospitals Case Medical Center, Cleveland, Ohio, USA
  2. Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China
  3. Institute of Mental Health of Second Xiangya Hospital of Central South University, Changsha, 410011, China
  4. Mood Disorders Program of Hongkou District Mental Health Center of Shanghai, Shanghai, 200083, China
  
• 刊物主题：Neurosciences; Human Physiology; Anesthesiology; Anatomy; Neurology; Pain Medicine;
• 出版者：Springer Berlin Heidelberg
• ISSN：1995-8218

文摘

English-language literature cited in MEDLINE from January, 1980 to October 30, 2014 was searched by using terms of antipsychotic, generic and brand names of atypical antipsychotics, “bipolar depression/bipolar disorder- “placebo- and “trial- The parameters of response (?0% improvement on MADRS, Montgomery-Asberg Depression Rating Scale total score), remission (either ?2 or 8 on MADRS total score at endpoint), discontinuation due to adverse events (DAEs), somnolence, ?% weight gain, overall extrapyramidal side-effects (EPSs), and akathisia, were extracted from originally published primary outcome papers. The number needed to treat to benefit (NNT) for response and remission or harm (NNH) for DAEs or other side effects relative to placebo were estimated and presented with the estimate and 95% confidence interval. Olanzapine monotherapy, olanzapine-fluoxetine combination (OFC), quetiapine-IR monotherapy, quetiapine-XR monotherapy, lurasidone monotherapy, and lurasidone adjunctive therapy were superior to placebo with NNTs for responses of 11-2, 4, 7-, 4, 4-, and 7, and NNTs for remission of 11-2, 4, 5-1, 7, 6-, and 6, respectively. There was no significant difference between OFC and lamotrigine, and between aripiprazole or ziprasidone and placebo in response and remission. Olanzapine monotherapy, quetiapine-IR, quetiapine-XR, aripiprazole, and ziprasidone 120-60 mg/day had significantly increased risk for DAEs with NNHs of 24, 8-4, 9, 12, and 10, respectively. For somnolence, quetiapine-XR had the smallest NNH of 4. For ?% weight gain, olanzapine monotherapy and OFC had the smallest NNHs with both of 5. For akathisia, aripiprazole had the smallest NNH of 5. These findings suggest that among the FDA-approved agents including OFC, quetiapine-IR and -XR, lurasidone monotherapy and adjunctive therapy to a mood stabilizer, the differences in the NNTs for response and remission are small, but the differences in NNHs for DAEs and common side-effects are large. Therefore, the selection of an FDA-approved atypical antipsychotic for bipolar depression should be based upon safety and tolerability. Keywords bipolar depression atypical antipsychotic number needed to treat efficacy tolerability weight gain somnolence extrapyramidal side-effects akathisia